ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Maraviroc (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms ENLIGHTEN
- 07 Feb 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Planned End Date changed from 30 Mar 2019 to 7 Dec 2018.
- 21 Sep 2018 Status changed from recruiting to active, no longer recruiting.